The FDA has announced a significant label revision for Microgestin 1/20, effective 2025-11-12, by adding a Boxed Warning. This critical update highlights that cigarette smoking substantially increases the risk of serious cardiovascular side effects from oral contraceptive use. The risk is particularly pronounced in women over 35 years of age and those who smoke 15 or more cigarettes per day.
Background
Microgestin 1/20 is an oral contraceptive. Oral contraceptives are widely prescribed for pregnancy prevention and other gynecological conditions. The FDA issues Boxed Warnings, also known as black box warnings, to call attention to serious or life-threatening risks associated with a drug. These warnings are the strongest safety alerts the FDA requires and are intended to ensure that healthcare providers and patients are fully informed about potential severe adverse events. The presence of such a warning indicates that the FDA has determined there is reasonable evidence of a serious hazard with the drug.
What this means
The addition of a Boxed Warning to the Microgestin 1/20 label reinforces the critical importance of thorough patient screening and counseling regarding smoking habits before initiating or continuing oral contraceptive therapy. Clinicians must carefully assess a patient's age and smoking status, emphasizing that the risk of serious cardiovascular events, such as thrombosis, myocardial infarction, and stroke, is significantly elevated in women aged 35 years or older who smoke, especially those consuming 15 or more cigarettes per day. This label change serves as a vital reminder for healthcare providers to discuss alternative contraceptive methods for at-risk individuals and to educate patients on the severe health consequences of combining smoking with oral contraceptive use. The revision aims to enhance patient safety by ensuring that both healthcare providers and patients are fully aware of these serious potential side effects, guiding more informed prescribing decisions and patient choices.
Source
This information is based on an FDA label revision for Microgestin 1/20, effective 2025-11-12. The details regarding the new Boxed Warning were published by the FDA on the DailyMed platform, hosted by dailymed.nlm.nih.gov.